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Abstract 
 
Murraya koenigii leaves (Rutaceae) are used traditionally in Indian 
Ayurvedic system to treat diabetes. The purpose of the study is to investigate 
the effect of mahanimbine (carbazole alkaloid from Murraya koenigii leaves) 
on blood glucose and serum lipid profiles on streptozotocin-induced diabetic 
rats. Diabetes was induced in adult male Wistar rats by intra-peritoneal 
injection of streptozotocin (45mg/kg). Mahanimbine (50 and 100mg/kg) were 
administrated as a single dose per week to the diabetic rats for 30 days. The 
control group received 0.3% w/v sodium carboxy methyl cellulose for the 
same duration. Fasting blood sugar and serum lipid profiles were measured in 
the diabetic and non-diabetic rats. In addition, in vitro alpha amylase and 
alpha glucosidase inhibitory effects of mahanimbine were performed.  
Results: In the diabetic rats, the elevated fasting blood sugar, triglycerides, 
low density lipoprotein, very low density lipoprotein levels were reduced and 
high density lipoprotein level was increased by mahanimbine at a dose of 50 
and 100mg/kg (i.p). In addition, mahanimbine showed appreciable alpha 
amylase inhibitory effect and weak alpha glucosidase inhibitory effects when 
compared with acarbose. Conclusions: The present study indicated that 
mahanimbine possess anti-hyperglycemic and anti-lipidemic effects. Thus 
results suggesting mahanimbine has beneficial effect in the management of 
diabetes associated with abnormal lipid profile and related cardiovascular 
complications. 
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Introduction 
Diabetes is a group of metabolic diseases 
characterized by hyperglycemia resulting from 
defects in insulin secretion or insulin action, or 
both [1]. Broad research on diabetes leads to a 
number of synthetic oral hypoglycemic agents 
like biguanides, sulphonylureas and 
thiozolidinediones being used to treat diabetes. 
But all have side effects associated with their 
uses [2]. On   other   hand,   traditional  medicinal  
 
plants with their various biological constituents 
have been used effectively by the communities 
since long time to treat diabetes. Several natural 
products such as alkaloids, flavonoids, 
terpenoids, saponins, polysaccharides and 
glycosides are isolated from medicinal plants and 
are being reported to possess anti-diabetic 
activities [3]. In addition, herbal drugs are 
extensively used to treat various diseases due to 
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their effectiveness, minimal side effects and 
relatively low cost [4]. Therefore, it is important 
to isolate the lead molecules from traditional anti-
diabetic plants. 
Murraya koenigii (Rutaceae) commonly known 
as “Curry Patta” (Hindi) is widely used as a spice 
and condiment in India and other tropical 
countries. Various parts of Murraya koenigii have 
been used in traditional or folk medicine for the 
treatment of rheumatism, traumatic injury and 
snake bite and it has been reported to have 
antioxidant, anti-diabetic and anti-dysenteric 
activities [5,6].  Mahanimbine is a carbazole 
alkaloid and present in leaves, stem bark and root 
of Murraya koenigii. Most of the carbazole 
alkaloids have been isolated from 
taxanonomically related plants of the genus 
Murraya, Glycosmic and Clausena from the 
family Rutaceae [7]. The Murraya species has 
richest source of carbazole alkaloids.  Further, 
Carbazole alkaloids has been reported for their 
various pharmacological activities such as anti-
tumor, anti-viral, anti-inflammatory, anti-
convulsant, diuretic and anti-oxidant activities 
[8]. Therefore, the present study was undertaken 
to evaluate anti-diabetic and anti-hyperlipidemic 
effects of mahanimbine (carbazole alkaloid) in 
streptozotocin-induced diabetic rats. 
 
Materials and methods 
Plant materials 
Murraya koenigii leaves (Rutaceae) were 
collected from the locality of IIT Kharagpur 
campus, West Bengal, India in the month of 
September and October 2007. The leaves were 
inspected to be healthy and botanically identified 
and authenticated by M. Senthilkumar, Plant 
Biotechnologist, Prathyusha Institute of 
Technology and Management, Chennai. The 
herbarium Murraya koenigii leaves was deposited 
in the Prathyusha Institute of Technology and 
Management (PITAM) against voucher no. 
PITAM/CH/00009/2007. Murraya koenigii 
leaves after collection were dried at room 
temperature (27-30ºC) for 25-30 days. After 
complete drying (inspection), the dried materials 
were grounded into fine powder using a domestic 
electric grinder (Product: GX 21, Bajaj 
appliances, Mumbai, India) and used for 
extraction. 
 
 
Figure 1: Structure of Mahanimbine 
 
Extraction and isolation 
The dried plant powder of Murraya koenigii 
leaves were extracted with petroleum ether (60-
80ºC) in a Soxhlet apparatus for 72 h. at room 
temperature. The total extract was concentrated 
under reduced pressure and kept at room 
temperature. A greenish solid (3.6%) was 
separated out. This was dissolved in petroleum 
ether (60-80ºC) and chromatographed using silica 
gel (60-120 mesh) column and eluted 
successively with petroleum ether and chloroform 
mixture. The fractions obtained with 50% 
petroleum ether (60-80ºC) in chloroform afforded 
compound-I (mahanimbine). The compound-I 
was subjected to preparative TLC gave pure 
mahanimbine (0.4%). 
 
General experiments procedure 
Melting point was determined in open capillary 
tube in SUNBIM melting point apparatus. 
HPTLC (CAMAG, Switzerland) analysis was 
performed using silica gel 60 F254 TLC plate. 
Mahanimbine was spotted (10µl) on a silica gel 
60 F254 (Merck, Darmstadt, Germany) TLC 
plate. The plate was air dried and then developed 
using the solvent system petroleum ether and 
chloroform (7:3) in a CAMAG- twin-trough glass 
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chamber previously saturated with mobile phase 
vapor for 20 min.  After developing the plate, it 
was dried at 105ºC for 15 min and then it was 
scanned using Scanner 3 (CAMAG, Switzerland) 
at 254nm using WinCATS 4 software. 
Confirmative test for mahanimbine (carbazole 
alkaloid) showed purple colour spot by spraying 
10% sulphuric acid on the TLC plate [9]. IR 
spectrum was recorded on Thermo Nicolet Nexus 
870 FT-IR Spectrophotometer using potassium 
bromide pellet. Mass spectrum was recorded on 
Electro-Spray Ionization Mass Spectroscopy 
(Waters, UK). 1H NMR (200MHZ) and 13C NMR 
(50MHZ) spectra were recorded in CDCl3 in a 
Bruker 200 NMR spectrometer using Topspin 
software. 
 
Animals 
Adult male Wistar Rats (weighing 150-200 g) 
were used for the investigation. Before the 
starting of the experiment, the animals were 
acclimatized to the laboratory conditions for a 
period of 2 weeks. They were maintained at an 
ambient temperature (25 ± 2 ºC) and relative 
humidity (40-60%), with 12/12 h of light/dark 
cycle. The animals were maintained on balance 
diet and water ad libitum. Institutional Animal 
Ethical Committee (IAEC) approved the study 
and all the experiments were carried out by 
following the guidelines of CPCSEA, India. 
 
Induction of diabetes and blood sample 
collection 
A freshly prepared solution of streptozotocin 
(45mg/kg) in 0.1M citrate buffer pH 4.5 was 
injected intra-peritoneally in overnight fasted 
rats. After 3 days, blood was collected in vials 
from the tail vein of overnight fasting rats as 
selected under guidance of a vet using the aseptic 
conditions and disposable kits. FBS level of 
blood was checked regularly up to the stable 
hyperglycemia stage, usually one week after 
streptozotocin injection. Animals with marked 
hyperglycemia (FBS 250 mg/dl) were selected 
for the study [10]. 
 
Experimental Design 
Group   I - Normal control 
Group II - Diabetic control 
Group III - Diabetic +50 mg/kg (i.p) 
mahanimbine 
Group IV – Diabetic +100 mg/kg (i.p) 
mahanimbine 
Group V -   Diabetic + 0.5   mg/kg (i.p) 
glibenclamide 
 
The experiment was carried on five groups (I, II, 
III, IV and V) of six rats each. Group-I served as 
normal control. Group-II served as diabetic 
control. Group III received 50 mg/kg (i.p) of 
Mahanimbine. Group IV received 100 mg/kg 
(i.p) of Mahanimbine. Group V received 0.5 
mg/kg (i.p) of Glibenclamide and served as 
positive  control.  The   pure   mahanimbine   was 
suspended in 0.3% w/v sodium carboxy methyl 
cellulose (Sodium CMC) as a vehicle and 
injected intra-peritoneally into rats once a week at 
a dose of 50 mg/kg and 100 mg/kg body weight, 
for 30 days. The blood samples were collected 
from each rat by retro-orbital venepucture. 
Biochemical parameters were estimated at the 
beginning and after 30 days of experiment. 
 
 
 
Figure 2: HPTLC analysis of Mahanimbine 
 
Biochemical parameters 
Biochemical parameters notably fasting blood 
sugar (FBS), total cholesterol (TC), triglycerides 
(TG), low-density lipoprotein (LDL), very low-
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density lipoprotein (VLDL) levels and high-
density lipoprotein (HDL) level in blood serum 
were measured spectrophotometrically (Semi-
Autoanalyzer, Microlab 300, Merck) by using 
diagnostic kits and reagents obtained from 
Merck, India.  
 
 
Figure 3: FTIR spectrum of Mahanimbine 
 
In vitro alpha amylase inhibitory assay 
The assay was carried out following the standard 
protocol with slight modifications [11]. Starch 
azure (2 mg) was suspended in a tube containing 
0.2ml of 0.5 M Tris-Hcl buffer (pH 6.9) 
containing 0.01 M calcium chloride (substrate). 
The tube was boiled for 5 min and then pre-
incubated at 37º C for 5 min. Mahanimbine 
(1mg) was dissolved in 1ml of 0.1% of dimethyl 
sulfoxide in order to obtain concentrations of 10, 
20, 40, 60, 80 and 100 µg/ml. Then 0.2 ml of 
mahanimbine of a particular concentration was 
put in the tube containing the substrate solution. 
0.1 ml of porcine pancreatic amylase in Tris-Hcl 
buffer (2units/ml) was added to the tube 
containing the mahanimbine and substrate 
solution. The process was carried out at 37º C for 
10 min. The reaction was stopped by adding 0.5 
ml of 50% acetic acid in each tube. The reaction 
mixture was then centrifuged (Eppendorf -5804 
R) at 3000 rpm for 5 min at 4º C. The absorbance 
of resulting supernatant was measured at 595nm 
using spectrophotometer (Perkin Elmer Lambda 
25 UV-VIS). The concentration of the 
mahanimbine required to inhibit 50% of alpha 
amylase activity under the conditions was defined 
as the IC50 value. The experiments were repeated 
thrice with the same protocol. The α-amylase 
inhibitory activity was calculated as follows: 
The α-amylase inhibitory activity = (Ac+) – (Ac-) – 
(As-Ab) / (Ac+) – (Ac-) × 100 
 Where, Ac+,  Ac-, As, Ab are defined as the 
absorbance of 100% enzyme activity (only 
solvent with enzyme), 0% enzyme activity (only 
solvent without enzyme), a test sample (with 
enzyme) and a blank (a test sample without 
enzyme) respectively. 
 
 
 
Figure 4: Alpha amylase and alpha glucosidase  
inhibitory effects of mahanimbine 
 
In vitro alpha glucosidase inhibitory assay 
The assay was performed with standard protocol 
[12]. Alpha glucosidase (2U/ml) was premixed 
with 20 µl of mahanimbine at various 
concentrations (10, 20, 40, 60, 80 and 100 µg/ml) 
and incubated for 5 min at 37ºC.  1mM para-
nitrophenyl gluco-pyanoside (20 µl) in 50mM of 
phosphate buffer (pH 6.8) was added to initiate 
the reaction. The mixture was further incubated at 
37ºC for 20 min. The reaction was terminated by 
addition of 50µl of 1M sodium carbonate and the 
final volume was made up to 150µl.  Alpha 
glucosidase activity was determined 
spectrophotometrically at 405nm on a Biorad 
microplate reader by measuring the quantity of 
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para-nitrophenol released from pNPG. The assay 
was performed in triplicate. The concentration of 
mahanimbine required to inhibit 50% of alpha 
glucosidase activity under the conditions was 
defined as the IC50 value. The experiments were 
repeated thrice with same protocol. 
 
Statistical analysis 
All values were expressed mean ± standard 
deviation. Statistical analysis of in vivo results 
were performed by one-way analysis of variance 
(ANOVA) followed by Student’s t-test.  P < 0.05 
was considered statistically significant. In vitro 
inhibitory assay statistical difference and linear 
regression analysis were performed using 
Graphpad prism 5 statistical software. 
 
Results 
Mahanimbine was isolated from Murraya 
koenigii leaves. Mahanimbine (Figure 1): white 
solid, C23H25NO, m.p 87-90ºC. In HPTLC 
analysis indicated the retention factor (Rf) values 
of mahanimbine was 0.34 (Figure 2). 
Confirmative test for mahanimbine showed 
purple colour spot (carbazole alkaloid). IR (KBr 
disc): 3440 (N-H), 2920, 1642 (C=C), 1456, 
1378, 1312 (C-N), 1211 (C-O), 1164, 741 cm-1 
(Figure 3).  In 1H NMR (CDCl3): data showed 
presence of aromatic methyl group at δ 2.34, gem 
dimethyl on a double bond at δ 1.58 and 1.66. A 
tertiary methyl adjacent to oxygen at a sharp 
singlet δ 1.45 and a triplet at δ 5.12 (1H). A 
multiplet at δ 2.12-2.17 along with gem dimethyl 
signals showed presence of iso-prenyl side chain. 
A triplet at δ 1.77 (2H) and two doublets at δ 5.67 
(1H) and 6.67 (1H) along with tertitary methyl 
signal, showed presence of a 2, 2 dimethyl 
chromene ring linked by an iso-prenyl side chain. 
The signals at δ 7.38 (d, 1H), 7.17 (t, 1H), 7.30 (t, 
1H) and 7.93 (d, 1H) indicated showed presence 
of other ring protons. The signal at 7.89 showed 
due to presence of N-H proton. In 13C NMR 
(CDCl3): data showed signal at δ16.04 due to 
presence of aromatic methyl signal on C3. Signals 
at δ 78.19, 128.48, 124.25, 22.78 and 17.57 
showed presences of 2, 2 dimethyl chromene 
rings on C1 and C2 in carbazole moiety. Signals at 
104.22, 116.67, 118.40 and 123.98 were due to 
presence of C1, C12, C11 and C3 respectively. The 
signals at δ 110.39, 117.56, 119.47, 121.90 and 
124.21 showed presence of C8, C6, C4, C5 and C7 
respectively. The signals δ 25.64, 25.87, 40.85, 
119.28 and 131.64 indicated presence of an iso-
prenyl chain attached to one of the gem dimethyl 
of the 2, 2 dimethyl chromene unit. The 
remaining tweleve signals unequivocally 
confirmed the presence of carbazole nucleus. 
ESI-MS (m/z, % intensity): m/z 354 [M-H]-.  
    The body weight was slightly increased in 
normal control rats compared to initial body 
weight whereas streptozotocin-induced diabetic 
rats showed loss of body weight (173.1 ± 0.57g) 
after 30 days as compared with initially weight of 
diabetic rats (198.3 ± 0.64g). However, body 
weight of diabetic rats was restored by treating 
with glibenclamide (0.5 mg/kg) and 
mahanimbine (at a dose of 50 mg/kg and 100 
mg/kg, i.p) once a week for 30 days (Table 1).  
 
Table 1: Body weights of streptozotocin-
induced diabetic rats after treatment with 
Mahanimbine 
 
  Group Initial body 
weight 
Final body 
weight 
Normal 
control                
195.5 ± 0.49       203.8 ± 1.31 
Diabetic 
control                
198. 3 ± 0.64      173.1 ± 0.57* 
50 mg/kg 
mahanimbine 
194.2 ± 0.63       188.3 ± 0.71* 
100 mg/kg 
mahanimbine 
192.1 ± 0.74   186.2 ± 0.69* 
0.5 mg/kg of 
glibenclamide    
187.0 ± 0.53       179.1 ± 0.69* 
 
Values are expressed as mean ± S.D. * P <0.05, treated 
diabetic groups Vs diabetic control group. 
 
Streptozotocin treatment resulted in elevation of 
fasting blood glucose, triglycerides, total 
cholesterol, low density lipoprotein and very low 
density lipoprotein and reduction in high density-
lipoprotein levels as compared to the normal 
control rats as noted at end of the study (Table 2). 
When diabetic rats treated with mahanimbine (at 
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a dose of 50mg/kg and 100 mg/kg, i.p) once a 
week for 30 days showed significant (P < 0.05) 
reduction in fasting blood sugar levels (217.0 ± 
0.61 mg/dl and 198.0 ± 0.84 mg/dl respectively). 
However, the standard drug glibenclamide 
(0.5mg/kg, i.p) exhibited potent anti-diabetic 
activity with maximum reduction of fasting blood 
sugar level (175.4 ± 0.77 mg/dl) on 30 days as 
compared  to  the  diabetic  control.  There  was  a 
significant (P < 0.05)  reduction in triglycerides, 
total cholesterol, low density lipoprotein and very 
low density lipoprotein levels of diabetic rats 
treated with mahanimbine (50 and 100mg/kg, i.p) 
as comparable to diabetic control. However, there 
was a significant (P < 0.05) elevation of HDL 
level in mahanimbine (50 and 100mg/kg, i.p) 
treated diabetic rats on 30 days as compared to 
the diabetic control group. 
  
 
Table 2: Effect of Mahanimbine on FBS, TC, TG, HDL, LDL and VLDL in normal and diabetic rats 
for 30 days 
 
BBP       Days Group 1       Group 2         Group 3 Group 4   Group 5 
FBS 
 (mg/dl)       0         85.3 ± 1.6         265.0 ± 1.3          241.1 ± 0.50      226.2 ± 0.47      215.1 ± 1.67 
                    30       92.2 ± 1.5         318.0 ± 0.74#       217.0 ± 0.61*   198.0 ± 0.84*    175.4 ± 0.77*  
TC  
 (mg/dl)       0         86.1 ± 1.48      176.2 ± 0.49         171.3 ± 0.81      168.1 ± 0.87      157.3 ± 0.60   
                    30       89.0 ± 0.73      196.4 ± 0.94#       162.5 ± 0.78*    151.4 ± 0.36*    148.7 ± 0.65*   
  TG 
(mg/dl)        0        85.4 ± 0.54      154.5 ± 0.49         148.4 ± 0.75      141.3 ± 0.57      138.5 ± 0.80    
                    30      91.0 ± 0.98       188.7 ± 0.58#       134.1 ± 0.67*   117.1 ± 0.64*     105.1 ± 0.65*  
  HDL  
(mg/dl)        0       32.5 ± 0.80       31.0 ± 0.61           33.0 ± 0.77        35.2 ± 0.75       37.1 ± 0.71  
                    30      34.1 ± 0.80       28.2 ± 0.57#         36.3 ± 0.72*      39.4 ± 0.70*     42.0 ± 0.64*   
  LDL  
(mg/dl)        0        45.2 ± 0.60      120.3 ± 0.75          115.5 ± 0.84      107.5 ± 0.57      98.7±0.63       
                    30      47.0 ± 0.61       132.0 ± 0.71#        102.1 ± 0.55*    97.7 ± 0.53*       87.5 ± 0.69* 
VLDL  
 (mg/dl)       0        20.4 ± 0.71      43.2 ± 0.66           41.2 ± 0.71        38.6 ± 0.65         35.4 ± 0.74  
                    30      22.1 ± 0.75       49.1 ± 0.69#         33.0 ± 0.61*      27.1 ± 0.83 *      21.1 ± 0.71* 
 
Values are expressed as mean ± S.D. n=6/group.  Group-I served as normal control. Group-II served as diabetic control. Group 
III received 50 mg/kg (i.p) of mahanimbine. Group IV received 100 mg/kg (i.p) of mahanimbine. Group V received 0.5 mg/kg 
(i.p) of glibenclamide (positive control). BBP-Biochemical parameters, FBS-fasting blood sugar, TC-total cholesterol, TG-
triglycerides, LDL-low-density lipoprotein, VLDL-very low-density lipoprotein, HDL-high-density lipoprotein. # P <0.05, 
Group 1 vs. Group 2. * P <0.05, treated diabetic groups vs. diabetic control group. 
 
Mahanimbine showed appreciable alpha amylase 
inhibitory effects (IC50 value of 83.72 ± 
1.4µg/ml) and a weak alpha glucosidase (IC50 
value of 99.89 ± 1.2µg/ml) as compared with 
acarbose (IC50 value of 83.33 ± 1.8µg/ml) (Figure 
4). 
 
Discussion 
The present study was designed to explore the 
effect of mahanimbine (carbazole alkaloid from 
Murraya koenigii leaves) on blood glucose and 
serum lipid profiles on streptozotocin-induced 
diabetic rats. When compared FTIR, ESI-MS, 1H 
NMR and 13C NMR spectra of isolated 
mahanimbine with the previously reported 
mahanimbine showed significant similarity [13, 
14]. 
Intra-peritoneal administration of 50mg/kg and 
100 mg/kg of mahanimbine once a week for 30 
days showed anti-diabetic and hypolipidemic 
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effects in diabetic rats. Since, lipid abnormalities 
accompanying with atherosclerosis is the major 
cause of cardiovascular disease in diabetes. 
Therefore ideal treatment of diabetes, in addition 
to glycemic control, should have a favorable 
effect on lipid profiles.  High level of TC and 
LDL are major coronary risk factors [15]. 
Further, several studies suggested that TG itself is 
indendently related to coronary heart disease [16, 
17]. The abnormalities in lipid metabolism lead 
to elevation in the levels of serum lipid and 
lipoprotein that in turn play an important role in 
occurrence of premature and severe 
atherosclerosis, which affects patients with 
diabetes [18]. Hence, measurements of 
biochemical parameters are necessary to prevent 
cardiac complications in diabetes condition.  
In the present study, an increase in blood sugar 
levels in diabetic rats was observed after the 
induction of diabetes by streptozotocin. This was 
prevented by treating diabetic rats with 
mahanimbine (at a dose 50 and 100 mg/kg, i.p) 
once in a week for 30 days. The standard drug 
glibenclamide has been used to treat diabetes, 
which stimulate insulin secretion from pancreatic 
beta cells, it may be suggested that the 
mechanism of action of mahanimbine is similar 
to glibenclamide. Several alkaloids had been 
reported to possess similar anti-diabetic effects of 
glibenclamide [19-20]. The possible mechanism 
by which the mahanimbine decreases blood sugar 
level may be by potentiating of insulin effect 
either by increasing the pancreatic secretion of 
insulin from beta cells of islets of langerhans or 
by increasing the peripheral glucose uptake. The 
mahanimbine (at a dose 50 and 100 mg/kg, i.p) 
treated diabetic rats showed a significant 
reduction in both fasting blood sugar levels and 
serum lipid profiles (TC, TG, LDL, and VLDL).  
There are several studies regarding the biological 
activity of carbazole alkaloids. Many carbazole 
alkaloids such as mukonicine, isomurrayazoline, 
koenoline, isomahanine, murrayanol and 
mahanimbine were isolated from different parts 
(leaves, stem bark, seed) of Murraya Koenigii 
[21-25]. Carbazole alkaloid and 
benzoisofuranone derivative isolated from stem 
bark of Murraya koenigii showed antimicrobial 
activity [26]. Some of the isolated carbazole 
alkaloids and their derivative from Murraya 
koenigii leaves showed anti-trichomonal activity 
[27]. Three carbaozole alkaloids (namely, 
Mahanine, Pyrayafoline-D and Murrayafoline –I) 
were isolated from Murraya koenigii leaves and 
reported that these alkaloids could be used for 
treatment of cancer as chemopreventive agents 
[28]. Murraya koenigii leaves extract showed the 
therapeutic protective nature in diabetes by 
decreasing oxidative stress and pancreatic beta 
cell damage [29]. Different doses of curry leaves 
(5, 10 and 15%) were given to normal rats, mild 
and moderate diabetic rats for 7 days. The results 
showed that Murraya koenigii could be useful for 
management of pre-diabetic state or mild diabetes 
[30]. The carbazole alkaloids (koenimbine and 
kurryam) were isolated from Murraya koenigii 
seed and oral administration of 50 mg/kg of 
koenimbine and kurryam exhibited significant 
ant-diarrhoeal effects in castor oil-induced 
diarrhoea rats [31]. 
In this study, treatment with mahanimbine (at a 
dose 50 and 100 mg/kg, i.p) once a week for 30 
days caused significant reduction in fasting blood 
glucose level of diabetic rats. This is an 
interesting, as the treatment with dose of 50 and 
100 mg/kg mahanimbine will not result in 
hypoglycemic shock in diabetic rats. Treatment 
with mahanimbine (at a dose 50 and 100 mg/kg, 
i.p) for 30 days significantly reduced total 
cholesterol, triglycerides, low density lipoprotein 
and very low density lipoprotein associated with 
significant increase in HDL levels in diabetic 
rats. Since HDL is responsible for the 
transportation of cholesterol from peripheral 
tissues to the liver for metabolism. The weight 
loss in diabetic rats may be associated with lipid 
lowering activity of mahanimbine or due to its 
influence on various lipid regulation systems. 
Hence, treatment with mahanimbine (at a dose 
50mg/kg and 100 mg/kg body weight) in diabetic 
rats has potential role to prevent formation of 
atherosclerosis and coronary heart disease.  
Therefore, our in vivo study clearly indicated that 
intra-peritoneal administration of mahanimbine 
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(carbazole alkaloid from Murraya koenigii 
leaves) at a dose 50 and 100 mg/kg exhibited 
anti-diabetic and hypolipidemic effects in 
streptozotocin-induced diabetic rats.  
In addition, one of the therapeutic approaches for 
Type 2 diabetes is to reduce the post-prandial 
hyperglycemia. Alpha amylase and alpha 
glucosidase are the enzymes involved in the 
metabolism of carbohydrates. Alpha amylase 
degrades complex dietary carbohydrates to 
oligosaccharides and disaccharides, which are 
ultimately converted into monosaccharide by 
alpha glucosidase. Liberated glucose is then 
absorbed by the gut and results in postprandial 
hyperglycemia. Inhibition of alpha amylase and 
alpha glucosidase limits postprandial glucose 
levels by delaying the process of carbohydrate 
hydrolysis and absorption [32]. The plant based 
alpha amylase and alpha glucosidase inhibitor 
offers a prospective therapeutic approach for the 
management of post-prandial hyperglycemia 
[33]. In the present study, mahanimbine showed 
appreciable alpha amylase inhibitory effects and 
a weak alpha glucosidase inhibitory effect as 
compared with acarbose. Therefore, 
mahanimbine might be useful in management of 
postprandial hyperglycemia.  
 
Conclusion 
The present study demonstrated that 
mahanimbine exhibited anti-diabetic and 
hyolipidemic effects in streptozotocin-induced 
diabetic rats. Therefore, mahanimbine could be 
used as anti-diabetic agent in the management of 
diabetes associated with abnormalities of lipid 
profiles. 
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